Literature DB >> 31836469

Evaluation of the clinical impact of the revised ISSHP and ACOG definitions on preeclampsia.

Anisha R Bouter1, Johannes J Duvekot2.   

Abstract

BACKGROUND: In 2018/2013 both ISSHP and ACOG revised their original statements and postulated new criteria for preeclampsia with and without severe features. Most importantly, preeclampsia can now also be established in the absence of proteinuria when other specific symptoms are present.
OBJECTIVE: What is the clinical impact of the use of three different new definitions for the diagnosis of preeclampsia? STUDY
DESIGN: Retrospective cohort study of all pregnant women who gave birth in the Erasmus MC between 01 and 01-2014 and 01-01-2016. Hypertensive disorders of pregnancy (HDP) were defined when blood pressure was elevated at least during two occasions. All HDP cases were classified according to the ISSHP 2001, ISSHP 2018 and ACOG 2013 definitions.
RESULTS: In our cohort (N = 4395) 878 patients had HDP (20,0%). The ISSHP 2018/ACOG 2013 definition cause a significant increase in patients with (superimposed) preeclampsia versus the ISSHP 2001 definition, from 272 patients (6,2%) to respectively 360 (8,2%)/290 (6,6%) (p < 0,001/p < 0,001). This increase is due to non-proteinuric preeclampsia cases. According to the ACOG 2013 definition there were 154 (53,1%) cases of preeclampsia with severe features. Neonatal NICU admission rates were almost doubled in the proteinuric preeclampsia group compared to the non-proteinuric preeclampsia group. DISCUSSION: Implementation of the ISSHP 2018/ACOG 2013 definitions cause a shift from gestational hypertension and chronic hypertension towards (superimposed) preeclampsia (relative increase 10%/2%). These increases are caused by inclusion of non-proteinuric cases. More research is necessary into the course and prognosis of especially non-proteinuric preeclampsia cases.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Criteria; Definitions; Preeclampsia; Proteinuria

Mesh:

Year:  2019        PMID: 31836469     DOI: 10.1016/j.preghy.2019.11.011

Source DB:  PubMed          Journal:  Pregnancy Hypertens        ISSN: 2210-7789            Impact factor:   2.899


  8 in total

Review 1.  Human Leukocyte Antigens in Pregnancy and Preeclampsia.

Authors:  Omonigho Aisagbonhi; Gerald P Morris
Journal:  Front Genet       Date:  2022-04-27       Impact factor: 4.772

2.  A novel regulated network mediated by downregulation HIF1A-AS2 lncRNA impairs placental angiogenesis by promoting ANGPTL4 expression in preeclampsia.

Authors:  Lijun Shu; Cong Wang; Zhengzheng Ding; Jianjiao Tang; Yuanyuan Zhu; Liuxin Wu; Zheyue Wang; Tingting Zhang; Tianjun Wang; Yetao Xu; Lizhou Sun
Journal:  Front Cell Dev Biol       Date:  2022-08-09

Review 3.  Ferroptosis and Its Emerging Role in Pre-Eclampsia.

Authors:  Zhixian Chen; Jianfeng Gan; Mo Zhang; Yan Du; Hongbo Zhao
Journal:  Antioxidants (Basel)       Date:  2022-06-28

Review 4.  A global view of hypertensive disorders and diabetes mellitus during pregnancy.

Authors:  Li Jiang; Kun Tang; Laura A Magee; Peter von Dadelszen; Alec Ekeroma; Xuan Li; Enyao Zhang; Zulfiqar A Bhutta
Journal:  Nat Rev Endocrinol       Date:  2022-09-15       Impact factor: 47.564

5.  Editorial to Special Issue.

Authors:  Sebastian Kwiatkowski
Journal:  Children (Basel)       Date:  2022-08-05

Review 6.  Reviewing Accuracy of First Trimester Screening for Preeclampsia Using Maternal Factors and Biomarkers.

Authors:  Sarah L Malone; Rani Haj Yahya; Stefan C Kane
Journal:  Int J Womens Health       Date:  2022-09-19

Review 7.  A Critical Review on the Use of Race in Understanding Racial Disparities in Preeclampsia.

Authors:  Henrietta O Fasanya; Chu J Hsiao; Kendra R Armstrong-Sylvester; Stacy G Beal
Journal:  J Appl Lab Med       Date:  2021-01-12

Review 8.  Mechanisms of Key Innate Immune Cells in Early- and Late-Onset Preeclampsia.

Authors:  Ingrid Aneman; Dillan Pienaar; Sonja Suvakov; Tatjana P Simic; Vesna D Garovic; Lana McClements
Journal:  Front Immunol       Date:  2020-08-18       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.